<DOC>
	<DOC>NCT02823964</DOC>
	<brief_summary>Liprotamase consists of 3 soluble, non-porcine digestive enzymes, lipase, protease, and amylase, combined in a fixed ratio. Liprotamase is stable in the stomach and can be formulated without enteric coating for administration either as a capsule or as a dosing solution dissolved in water or juice.</brief_summary>
	<brief_title>EASY: Extended Access to Sollpura Over Years</brief_title>
	<detailed_description>The purpose of the present study is to evaluate the safety of long-term use of liprotamase in the management of cystic fibrosis-related exocrine pancreatic insufficiency</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<criteria>Male or female subjects with cystic fibrosisrelated exocrine pancreatic insufficiency who received liprotamase and completed Study ANEPI3331 (SOLUTION: Study of Oral Liprotamase UnitMatched Therapy Of NonPorcine Origin in Patients With Cystic Fibrosis) Any medical, psychological, or social condition that may put the subject at increased risk by participating in this study. Females who are nursing, pregnant, intending to become pregnant, or intending to nurse during the time of the study.</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>exocrine pancreatic insufficiency</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>pancreatic enzyme replacement therapy</keyword>
</DOC>